You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

10 search results for: barrier dysfunction

Skin <b>Barrier</b> <b>Dysfunction</b> and Type 2 Inflammation in Atopic Dermatitis

videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

2 min

Dermatology

Learn more about how the exaggerated immune response due to chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

expert video

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

2 min

Gastroenterology

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

audio

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

4 min

Pulmonology

Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.

expert video

Connecting Type 2 Inflammation to CRSwNP

1 min

Rhinology

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

expert video

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis

10 min

Dermatology

In this ADVENT symposium at the 2024 Diversity in Dermatology conference, Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on how clinical signs and itch in atopic dermatitis and prurigo nodularis are impacted by type 2 inflammation.

expert video

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

42 min

Dermatology

In this ADVENT symposium at the 2024 Diversity in Dermatology conference, experts Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.

expert video

Is Pediatric AD Linked to Other Allergic Diseases?

2 min

Dermatology

In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region